RCKT EBITDA | Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (RCKT) EBITDA

2026-06-30: Basis Reported; EBITDA -$45.32M; Operating income (m); Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA -$46.91M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$42.26M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$49.55M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2018-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$45.32M	(m)	(m)	(m)	(m)	$8.00K*	-$39.61M*	(m)	$29.50M	(m)	$8.62M
2026-03-31	Reported	-$46.91M	(m)	(m)	(m)	(m)	$93.00K	-$45.39M	(m)	$31.45M	(m)	(m)
2025-12-31	Reported	-$42.26M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$49.55M	(m)	(m)	(m)	(m)	-$54.00K*	-$50.42M*	(m)	$34.07M	(m)	(m)
2025-06-30	Reported	-$69.15M	(m)	(m)	(m)	(m)	$50.00K*	-$48.96M*	(m)	$42.66M	(m)	$0.00
2025-03-31	Reported	-$61.89M	(m)	(m)	(m)	(m)	$364.00K	-$55.79M	(m)	$35.94M	(m)	(m)
2024-12-31	Reported	-$60.89M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$67.52M	(m)	(m)	(m)	(m)	$1.59M*	-$52.10M*	(m)	$42.31M	(m)	(m)
2024-06-30	Reported	-$71.91M	(m)	(m)	(m)	(m)	$1.93M*	-$53.82M*	(m)	$46.34M	(m)	(m)
2024-03-31	Reported	-$65.68M	(m)	(m)	(m)	(m)	$2.04M	-$56.86M	(m)	$45.23M	(m)	(m)
2023-12-31	Reported	-$61.88M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$64.23M	(m)	(m)	(m)	(m)	$4.66M*	-$57.15M*	(m)	$46.84M	(m)	(m)
2023-06-30	Reported	-$67.56M	(m)	(m)	(m)	(m)	$4.12M*	-$50.87M*	(m)	$51.38M	(m)	(m)
2023-03-31	Reported	-$61.09M	(m)	(m)	(m)	(m)	$3.02M	-$57.56M	(m)	$46.37M	(m)	(m)
2022-09-30	Reported	(m)	-$58.49M	(m)	$0.00	(m)	$503.00K*	-$43.86M*	(m)	$43.38M	(m)	(m)
2022-06-30	Reported	(m)	-$54.21M	(m)	$0.00	(m)	$2.90M*	-$39.04M*	(m)	$41.36M	(m)	(m)
2022-03-31	Reported	(m)	-$42.56M	(m)	$0.00	(m)	$1.96M	-$39.22M	(m)	$30.79M	(m)	(m)
2021-12-31	Reported	-$43.32M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$48.85M	(m)	(m)	(m)	(m)	$3.88M*	-$27.41M*	(m)	$39.62M	(m)	(m)
2021-06-30	Reported	-$33.35M	(m)	(m)	(m)	(m)	$1.45M*	-$38.53M*	(m)	$24.53M	(m)	(m)
2021-03-31	Reported	-$38.55M	(m)	(m)	(m)	(m)	$328.00K	-$24.28M	(m)	$28.31M	(m)	(m)
2020-12-31	Reported	-$58.61M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$27.09M	(m)	(m)	(m)	(m)	-$161.00K*	-$17.25M*	(m)	$21.66M	(m)	(m)
2020-06-30	Reported	-$23.46M	(m)	(m)	(m)	(m)	$1.91M*	-$22.03M*	(m)	$16.73M	(m)	(m)
2020-03-31	Reported	-$24M	(m)	(m)	(m)	(m)	$5.21M	-$22.25M	(m)	$16.96M	(m)	(m)
2019-12-31	Reported	-$19.55M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$19.07M	(m)	(m)	(m)	(m)	$6.71M*	-$10.85M*	(m)	$14.83M	(m)	(m)
2019-06-30	Reported	(m)	-$18.39M	(m)	$0.00	(m)	$6.54M*	-$18.10M*	(m)	$13.99M	(m)	(m)
2019-03-31	Reported	(m)	-$18.95M	(m)	$0.00	(m)	$760.00K	-$15.98M	(m)	$15.14M	(m)	(m)
2018-12-31	Reported	(m)	-$26.55M	(m)	$0.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	(m)	-$15.33M	(m)	$0.00	(m)	$453.00K*	-$11.63M*	(m)	$13.06M	(m)	(m)
2018-06-30	Reported	(m)	-$14.87M	(m)	$0.00	(m)	$109.00K*	-$9.74M*	(m)	$10.77M	(m)	(m)
2018-03-31	Reported	(m)	-$14.40M	(m)	$0.00	(m)	$8.00K	-$11.60M	(m)	$5.74M	(m)	(m)
2017-12-31	Reported	(m)	-$6.66M	(m)	$0.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$6.72M	(m)	$0.00	(m)	$1.00K*	-$4.09M*	(m)	$4.89M	(m)	(m)
2017-06-30	Reported	(m)	-$3.52M	(m)	$0.00	(m)	$598.00K*	-$2.16M*	(m)	$2.82M	(m)	(m)
2017-03-31	Reported	(m)	-$2.87M	(m)	$0.00	(m)	$131.00K	-$3.72M	(m)	$2.29M	(m)	(m)
2016-09-30	Reported	(m)	-$10.72M	(m)	(m)	(m)	(m)	(m)	(m)	$8.41M	(m)	(m)
2016-06-30	Reported	(m)	-$8.78M	(m)	(m)	(m)	(m)	(m)	(m)	$6.46M	(m)	(m)
2016-03-31	Reported	(m)	-$10.14M	(m)	(m)	(m)	(m)	(m)	(m)	$7.62M	(m)	(m)
2015-09-30	Reported	(m)	-$5.44M	(m)	(m)	(m)	(m)	(m)	(m)	$3.61M	(m)	(m)
2015-06-30	Reported	(m)	-$3.68M	(m)	(m)	(m)	(m)	(m)	(m)	$1.95M	(m)	(m)
2015-03-31	Reported	(m)	-$3.05M	(m)	(m)	(m)	(m)	(m)	(m)	$1.07M	(m)	(m)
2014-09-30	Reported	(m)	-$2.09M	(m)	(m)	(m)	(m)	(m)	(m)	$1.24M	(m)	(m)
2014-06-30	Reported	(m)	-$2.19M	(m)	(m)	(m)	(m)	(m)	(m)	$1.86M	(m)	(m)
2014-03-31	Reported	(m)	-$1.71M	(m)	(m)	(m)	(m)	(m)	(m)	$1.55M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$222.85M	(m)	(m)	(m)	(m)	$440.00K	-$190.01M	(m)	$142.01M	(m)	$0.00
2024-12-31	Reported	-$266.01M	(m)	(m)	(m)	(m)	$5.86M	-$209.72M	(m)	$171.24M	(m)	$0.00
2023-12-31	Reported	-$254.76M	(m)	(m)	(m)	(m)	$16.44M	-$194.92M	(m)	$186.34M	(m)	$0.00
2022-12-31	Reported	-$220.44M	(m)	(m)	(m)	(m)	$8.36M	-$178.14M	(m)	$165.57M	(m)	(m)
2021-12-31	Reported	-$164.05M	(m)	(m)	(m)	(m)	$7.62M	-$121.16M	(m)	$125.48M	(m)	(m)
2021-09-30	Rolling	(m)	-$182.15M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$159.89M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$149.41M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$133.16M	(m)	(m)	(m)	(m)	$20.61M	-$74.64M	(m)	$105.44M	(m)	(m)
2020-12-31	Rolling	(m)	-$134.30M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$94.72M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$86.49M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$81.33M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$75.73M	(m)	(m)	(m)	(m)	$23.27M	-$64.66M	(m)	$57.91M	(m)	(m)
2019-12-31	Rolling	(m)	-$76.15M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$83.05M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$79.22M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$75.70M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$70.83M	(m)	(m)	(m)	(m)	$1.45M	-$53.79M	(m)	$53.27M	(m)	(m)
2018-12-31	Rolling	(m)	-$71.16M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$51.27M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$42.66M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$31.31M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	(m)	-$19.77M	(m)	$0.00	(m)	$760.00K	-$15.96M	(m)	$14.92M	(m)	(m)
2017-12-31	Rolling	(m)	-$19.77M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	(m)	-$7.57M	(m)	$0.00	(m)	$335.00K	-$5.50M	(m)	$5.99M	(m)	(m)
2015-12-31	Reported	(m)	-$20.40M	(m)	(m)	(m)	(m)	(m)	(m)	$12.55M	(m)	(m)
2014-12-31	Reported	(m)	-$7.70M	(m)	(m)	(m)	(m)	(m)	(m)	$5.59M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
STANDARD BIOTOOLS INC. (LAB)	United States	$0.297B	3.80
Vanda Pharmaceuticals Inc. (VNDA)	United States	$0.302B	-1.35
Fulcrum Therapeutics, Inc. (FULC)	United States	$0.289B	-3.28
Contineum Therapeutics, Inc. (CTNM)	United States	$0.289B	-4.40
Perspective Therapeutics, Inc. (CATX)	United States	$0.284B	-3.34
Upstream Bio, Inc. (UPB)	United States	$0.284B	-2.42
GT Biopharma, Inc. (GTBP)	United States	$0.309B	-4.58
ABEONA THERAPEUTICS INC. (ABEO)	United States	$0.312B	-5.63
Sagimet Biosciences Inc. (SGMT)	United States	$0.279B
Prelude Therapeutics Inc (PRLD)	United States	$0.318B	-7.01